Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vytrus Biotech's share price for the quarter that ended in Dec. 2025 was €8.55. Vytrus Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 7.52 Mil. Therefore, Vytrus Biotech's market cap for the quarter that ended in Dec. 2025 was €64.26 Mil.
Vytrus Biotech's quarterly market cap
increased
from Dec. 2024 (€16.25 Mil) to Jun. 2025 (€28.76 Mil) and
increased
from Jun. 2025 (€28.76 Mil) to Dec. 2025 (€64.26 Mil).
Vytrus Biotech's annual market cap
increased
from Dec. 2023 (€12.53 Mil) to Dec. 2024 (€16.25 Mil) and
increased
from Dec. 2024 (€16.25 Mil) to Dec. 2025 (€64.26 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vytrus Biotech's Enterprise Value for Today is €130.13 Mil.
Vytrus Biotech (XMAD:VYT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vytrus Biotech Market Cap Related Terms
Vytrus Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Vytrus Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vytrus Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (XMAD:VYT) has a Market Cap of €131.54 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vytrus Biotech and its competitors. According to the industry distribution chart, Vytrus Biotech ranks #664 out of 1421 companies in the Biotechnology industry, placing it in the top 46.7%.
Is Vytrus Biotech's Market Cap too high?
Vytrus Biotech's current Market Cap is €131.54 Mil. Based on the distribution chart, Vytrus Biotech ranks #664 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #664 out of 1421 companies for Market Cap. This puts Vytrus Biotech in the upper half of its industry. The industry median Market Cap is 119.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.86, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 119.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Market Cap is €131.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.54, compared to a current price of €17.50 — trading 215.9% above its estimated fair value. The current Market Cap is €131.54 Mil. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Market Cap is €131.54 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.50 is trading 215.9% above its estimated GF Value™ of €5.54.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Market Cap: €131.54 Mil
GF Value™: €5.54 vs. price of €17.50 (215.9% above fair value)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
